Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2007-9-11
pubmed:abstractText
High-dose methotrexate (MTX) and whole brain radiation therapy (WBRT) prolong survival in primary CNS lymphoma (PCNSL) patients but have been associated with delayed neurotoxicity. Consequently, patients are often treated with chemotherapy alone, and WBRT is deferred until relapse.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1526-632X
pubmed:author
pubmed:issnType
Electronic
pubmed:day
11
pubmed:volume
69
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1178-82
pubmed:meshHeading
pubmed-meshheading:17846417-Age Factors, pubmed-meshheading:17846417-Aged, pubmed-meshheading:17846417-Antineoplastic Agents, pubmed-meshheading:17846417-Brain, pubmed-meshheading:17846417-Brain Neoplasms, pubmed-meshheading:17846417-Female, pubmed-meshheading:17846417-Humans, pubmed-meshheading:17846417-Lymphoma, pubmed-meshheading:17846417-Male, pubmed-meshheading:17846417-Middle Aged, pubmed-meshheading:17846417-Neoplasm Recurrence, Local, pubmed-meshheading:17846417-Nerve Degeneration, pubmed-meshheading:17846417-Radiation Dosage, pubmed-meshheading:17846417-Radiotherapy, pubmed-meshheading:17846417-Retrospective Studies, pubmed-meshheading:17846417-Risk Assessment, pubmed-meshheading:17846417-Risk Factors, pubmed-meshheading:17846417-Survival Rate, pubmed-meshheading:17846417-Treatment Outcome
pubmed:year
2007
pubmed:articleTitle
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.
pubmed:affiliation
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
pubmed:publicationType
Journal Article